**CARDIOVASCULAR OUTCOMES OF AMLODIPINE-BASED COMBINATION THERAPIES IN HIGH-RISK HYPERTENSIVE PATIENTS**

**P.P. Lu**1, X. Meng1, A.H. Hu2, W. Wang2, L.Y. Ma1, Y.Q. Zhang1, X.Z. Zhang2, L.H. Ma1,

L.S. Liu2, X.L. Zhou1

1Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Bei Jing, China

2Beijing Hypertension League Institute, Chinese Hypertension League, Bei Jing, China

**Objective:** To evaluate the treatment efficacy with the combination of a dihydropyridine calcium-channel blocker amlodipine with diuretics or angiotensin II receptor blocker on reducing the rate of cardiovascular events.

**Methods:**In a randomized, open-label, blinded-endpoint trial, hypertensive patients at high risk for cardiovascular events from 180 clinical centers in China were assigned to receive treatment with either amlodipine plus amiloride/hydrochlorothiazide (n=6776) or telmisartan (n=6766). The primary outcome was the composite of nonfatal stroke, nonfatal myocardial infarction or death from cardiovascular causes.

**Results:**The median follow-up was 41 months. No between-group difference was observed in the mean BP lowering. However, the primary-outcome events were reduced by 23.7% in the amlodipine-diuretics group compared with the amlodipine-telmisartan group (hazard ratio [HR], 0.76; p=0.006). Of note, amlodipine-diuretics treatment significantly lowered the risk of cardiovascular death (HR, 0.64; p=0.035) and fatal and nonfatal stroke (HR, 0.78; p=0.037) relative to amlodipine-telmisartan combination. Both treatments were safe and well tolerated.

**Conclusion:**The amlodipine-diuretics combination was more efficacious in reducing cardiovascular events than the amlodipine-telmisartan combination in hypertensive patients with high risk for such events, independent of blood pressure reduction.

(ClinicalTrials.gov number, NCT01011660)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table 1: Hazard ratios for primary, secondary and other outcomes. | | | | |
| **Outcome-no. (%)** | **Amlodipine-Diuretics Group (N=6776)** | **Amlodipine-Telmisartan Group (N=6766)** | **Hazard Ratio (95% CI)** | **P value** |
| Primary outcome | 179 (2.6) | 235 (3.5) | 0.76 (0.63, 0.93) | 0.006 |
| Fatal and nonfatal stroke | 127 (1.9) | 163 (2.4) | 0.78 (0.62, 0.99) | 0.037 |
| Death from cardiovascular causes | 37 (0.5) | 58 (0.9) | 0.64 (0.43, 0.97) | 0.035 |
| Fatal and nonfatal myocardial infarction | 35 (0.5) | 38 (0.6) | 0.93 (0.59, 1.47) | 0.747 |
| Hospitalization for unstable angina | 49 (0.7) | 60 (0.9) | 0.82 (0.56,1.20) | 0.312 |
| Coronary revascularization | 33 (0.5) | 48 (0.7) | 0.69 (0.44,1.08) | 0.104 |
| Hospitalization for congestive heart failure | 6 (0.1) | 16 (0.2) | 0.38 (0.15, 0.97) | 0.042 |
| Composite of cardiovascular events | 192 (2.8) | 243 (3.6) | 0.79 (0.66, 0.96) | 0.016 |
| Death from any cause | 110 (1.6) | 98 (1.4) | 1.13 (0.86, 1.48) | 0.385 |